title: Retrospective Study of 122 Dogs That Were Treated with the Antifibrinolytic Drug Aminocaproic Acid: 2010-2012.
abstract: Antifibrinolytic drugs are used to promote hemostasis and decrease the need for red blood cell transfusion. Medical records of 122 dogs that were prescribed either oral or intravenous aminocaproic acid between 2010 and 2012 were evaluated retrospectively. Of the 122 dogs, three experienced possible drug-related adverse effects. No significant differences were identified between dogs that experienced adverse effects and those that did not and the possible adverse effects noted were all minor. All dogs that received packed red blood cell transfusions were evaluated for correlations between baseline packed cell volume or dose of red blood cells and aminocaproic acid dose and no correlation was identified. Dogs that received aminocaproic acid as a treatment for active bleeding were divided by cause of hemorrhage into the following groups: neoplastic, non-neoplastic, and unknown. No significant differences in aminocaproic acid dose or the percentage of patients requiring a blood transfusion were identified between groups.
authors.affiliation: From the Department of Emergency/Critical Care, Angell Animal Medical Center, Boston, MA.
authors.forename: Megan
authors.initials: M
authors.lastname: Davis
authors.affiliation: From the Department of Emergency/Critical Care, Angell Animal Medical Center, Boston, MA.
authors.forename: Kiko
authors.initials: K
authors.lastname: Bracker
mesh_terms: D015119:Aminocaproic Acid / Q000627:therapeutic use*; D000818:Animals; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D016063:Blood Loss, Surgical; D004283:Dog Diseases / Q000517:prevention & control*; D004285:Dogs; D017707:Erythrocyte Transfusion / Q000662:veterinary*; D006470:Hemorrhage / Q000517:prevention & control / Q000662:veterinary*; D012189:Retrospective Studies
chemical_list: D000933:Antifibrinolytic Agents; D015119:Aminocaproic Acid